NTB-3119

NTB-3119 exhibited potent in vitro activity against both drug-susceptible and drug-resistant tuberculosis clinical strains. In addition, it displayed potent in vivo efficacy with bactericidal activity in an acute mouse model of tuberculosis. NTB-3119, developed by Institute of Materia Medica, Chinese Academy of Medical Sciences, is under evaluation as a potential clinical candidate for treatment of tuberculosis.NTB-3119 exhibited potent in vitro activity against both drug-susceptible and drug-resistant tuberculosis clinical strains. In addition, it displayed potent in vivo efficacy with bactericidal activity in an acute mouse model of tuberculosis. NTB-3119, developed by Institute of Materia Medica, Chinese Academy of Medical Sciences, is under evaluation as a potential clinical candidate for treatment of tuberculosis.